Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study
- PMID: 27549867
- DOI: 10.4103/0378-6323.188652
Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study
Abstract
Background: Finasteride and dutasteride are inhibitors of the enzyme 5-alpha-reductase which inhibits the conversion of testosterone to dihydrotestosterone. Dutasteride inhibits both type I and type II 5-alpha-reductase while finasteride inhibits only the type II enzyme. As both isoenzymes are present in hair follicles, it is likely that dutasteride is more effective than finasteride.
Aims: To compare the efficacy, safety and tolerability of dutasteride and finasteride in men with androgenetic alopecia.
Methods: Men with androgenetic alopecia between 18 and 40 years of age were randomized to receive 0.5 mg dutasteride or 1 mg finasteride daily for 24 weeks. The primary efficacy variables were hair counts (thick and thin) in the target area from modified phototrichograms and global photography evaluation by blinded and non-blinded investigators. The secondary efficacy variable was subjective assessment using a preset questionnaire. Patients were assessed monthly for side effects.
Results: Ninety men with androgenetic alopecia were recruited. The increase in total hair count per cm[2] representing new growth was significantly higher in dutasteride group (baseline- 223 hair; at 24 weeks- 246 hair) compared to finasteride group (baseline- 227 hair; at 24 weeks- 231 hair). The decrease in thin hair count per cm[2] suggestive of reversal of miniaturization was significantly higher in dutasteride group (baseline- 65 hair; at 24 weeks- 57 hair) compared to finasteride group (baseline- 67 hair; at 24 weeks- 66 hair). Both the groups showed a similar side effect profile with sexual dysfunction being the most common and reversible side effect.
Limitations: Limitations include the short duration of the study (6 months), the small sample size and the fact that it was an open-label study.
Conclusions: Dutasteride was shown to be more efficacious than finasteride and the side-effect profiles were comparable.
Similar articles
-
A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3. doi: 10.1016/j.jaad.2013.10.049. Epub 2014 Jan 9. J Am Acad Dermatol. 2014. PMID: 24411083 Clinical Trial.
-
Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.J Dermatol. 2016 Sep;43(9):1051-8. doi: 10.1111/1346-8138.13310. Epub 2016 Feb 19. J Dermatol. 2016. PMID: 26893187 Clinical Trial.
-
Dutasteride in Androgenetic Alopecia: An Update.Curr Clin Pharmacol. 2017;12(1):31-35. doi: 10.2174/1574884712666170310111125. Curr Clin Pharmacol. 2017. PMID: 28294070 Review.
-
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035. Acta Derm Venereol. 2019. PMID: 30206635
-
Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.Dermatol Online J. 2017 Nov 11;23(11):13030/qt24k8q743. Dermatol Online J. 2017. PMID: 29447628 Review.
Cited by
-
Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study.Ann Dermatol. 2022 Oct;34(5):349-359. doi: 10.5021/ad.22.027. Ann Dermatol. 2022. PMID: 36198626 Free PMC article.
-
Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinson's Disease.Pharmaceuticals (Basel). 2023 Jan 20;16(2):152. doi: 10.3390/ph16020152. Pharmaceuticals (Basel). 2023. PMID: 37259303 Free PMC article.
-
Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials.Cureus. 2023 Jul 31;15(7):e42768. doi: 10.7759/cureus.42768. eCollection 2023 Jul. Cureus. 2023. PMID: 37663989 Free PMC article. Review.
-
The 100 most cited articles in androgenetic alopecia: A bibliometric analysis.Medicine (Baltimore). 2025 Mar 21;104(12):e41881. doi: 10.1097/MD.0000000000041881. Medicine (Baltimore). 2025. PMID: 40128083 Free PMC article.
-
Topical dutasteride for androgenic alopecia: current state and prospects.Ther Deliv. 2025 Mar;16(3):271-283. doi: 10.1080/20415990.2024.2437973. Epub 2024 Dec 6. Ther Deliv. 2025. PMID: 39641480 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
